BRAF and lung carcinoma: In colorectal and lung cancers, due to their higher baseline RTK activity, the resulting RAS activity is sufficient to support the activation of class III BRAF mutants; therefore, only a minority of class III BRAF-mutation cases coexist with RAS/NF1 mutations.38